122 related articles for article (PubMed ID: 1694086)
1. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.
Price P; Hogan SJ; Horwich A
Eur J Cancer; 1990 Apr; 26(4):450-3. PubMed ID: 1694086
[TBL] [Abstract][Full Text] [Related]
2. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
Price P; Hogan SJ; Bliss JM; Horwich A
Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
[TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
4. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
6. [Tumor marker diagnosis in non-seminomatous testicular tumors using human chorionic gonadotropin (HCG) and alpha fetoprotein (AFP)].
Boewer C; Nawka S; Fleck H; Uibel M; Immer U; Schmidt HE; Herzmann H; Pilgrim G; Ziegenbein R
Z Urol Nephrol; 1985 Feb; 78(2):77-86. PubMed ID: 2581393
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
8. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
von Eyben FE; Blaabjerg O; Madsen EL; Petersen PH; Smith-Sivertsen C; Gullberg B
Eur J Cancer; 1992; 28(2-3):410-5. PubMed ID: 1375486
[TBL] [Abstract][Full Text] [Related]
9. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
[TBL] [Abstract][Full Text] [Related]
10. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
Seckl MJ; Rustin GJ; Bagshawe KD
Br J Cancer; 1990 Jun; 61(6):916-8. PubMed ID: 1695522
[TBL] [Abstract][Full Text] [Related]
11. Germ cell tumours of testis: prognostic factors and results.
Nikzas D; Champion AE; Fox M
Eur Urol; 1990; 18(4):242-7. PubMed ID: 1705226
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin.
Fottner C; Sattarova S; Hoffmann K; Spöttl G; Weber MM
Eur J Endocrinol; 2008 Sep; 159(3):317-27. PubMed ID: 18524796
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis.
Raghavan D; Peckham MJ; Heyderman E; Tobias JS; Austin DE
Br J Cancer; 1982 Feb; 45(2):167-73. PubMed ID: 6174137
[TBL] [Abstract][Full Text] [Related]
14. Metastatic non-seminomatous germ cell tumour and dermatomyositis.
Barker RA; Currie DC; Horwich A; Spiro SG
Postgrad Med J; 1990 Jan; 66(771):59-60. PubMed ID: 1693426
[TBL] [Abstract][Full Text] [Related]
15. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment.
Dieckmann KP; Simonsen-Richter H; Kulejewski M; Anheuser P; Zecha H; Isbarn H; Pichlmeier U
Biomed Res Int; 2019; 2019():5030349. PubMed ID: 31275973
[TBL] [Abstract][Full Text] [Related]
16. Serum estradiol as a tumour marker for non-seminomatous germinal cell tumours (NSGCT) of the testis.
Uysal Z; Bakkaloğlu M
Int Urol Nephrol; 1987; 19(4):415-8. PubMed ID: 2448261
[TBL] [Abstract][Full Text] [Related]
17. Testicular tumour markers in tissue correlated to serum levels and clinical stage.
Alm P; Hultberg B; Olsson AM
Scand J Urol Nephrol; 1984; 18(4):283-8. PubMed ID: 6209794
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours.
Lancet; 1985 Jan; 1(8419):8-11. PubMed ID: 2578205
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
20. Lactate dehydrogenase as a marker for testicular germ-cell tumours.
Taylor RE; Duncan W; Horn DB
Eur J Cancer Clin Oncol; 1986 Jun; 22(6):647-53. PubMed ID: 3017721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
